My site

(BUSINESS WIRE)--Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announced that several of its LTE modules are now available with Direct-to-Cell (D2C) functionality, enabling devices to seamlessly connect to satellite networks.

By integrating D2C technology at the module level, Quectel enables devices to extend beyond the limits of ground-based cellular networks by seamlessly leveraging satellite networks. This ensures customers can stay connected virtually anywhere in the world, eliminating the connectivity gaps often encountered in rural or remote areas. Ultimately, this will help to simplify IoT deployments, reducing time-to-market and lowering costs by eliminating the need for specialized satellite hardware. Device manufacturers and developers can now build scalable IoT solutions with global reach, ensuring reliable connectivity virtually anywhere.

“Direct-to-Cell represents a major step forward in connecting the unconnected,&r ... Read more »

BELGRADE, Serbia 
(BUSINESS WIRE) -- Quectel Wireless Solutions, a global IoT solutions provider, has introduced four new additions to its comprehensive range of global navigation satellite system (GNSS) antennas. The new antennas include the YFGD000AA high precision, low profile antenna which covers all GNSS bands, the YFGD000BA, optimized for triple-band solutions in GNSS L1, L2 and L5 bands, the YFGN000H1AC high precision, lightweight antenna that again covers all GNSS bands, and the YEGT010W1AM, designed for general-purpose reception in non-precision applications.

Quectel’s triple-band and all-band antennas are purpose-built to maximize performance with the latest generation of RTK GNSS modules. These include the LC29H dual-band module, designed for cost-sensitive yet precision-critical applications; the LG290P industrial-grade module, delivering centimetre-level accuracy with RTK fix times under five seconds; and the flagship LG580P, which adds L6 suppo ... Read more »

BRUSSELS - Thursday, 11. September 2025 AETOSWire  

(BUSINESS WIRE)--The Usage-Based Insurance (UBI) market has now reached over 60 million customers across 450 active programmes – a sixfold increase in just ten years. PTOLEMUS Consulting Group, which predicted the “uberisation” of insurance in 2015, highlights this transformation in its new report.

UBI is now a truly global phenomenon that reaches 59 countries and generates more than €50 billion in premiums, finds the consulting firm in its new report.

This growth reflects the growing smartphonisation of the business. Insurers increasingly embed UBI into their corporate apps, making it a central part of the customer experience.

At the same time, UBI has evolved beyond simple Pay-As-You-Drive (PAYD) or Pay-How-You-Drive (PHYD) models. It is now a proven tool for reducing the frequency and severity of claims, delivering measurable savings to both insurers and policyholders.< ... Read more »

LAS VEGAS - 
(BUSINESS WIRE) -- Rimini Street, Inc., (the “Company”) (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the completion of the following capital market transactions thus far during the third fiscal quarter of 2025:

Repurchased a total of 891,000 shares of common stock for approximately $3.8 million with an average per share purchase price of $4.22, reducing approximately 1.0% of shares outstanding as of July 28, 2025. The Rimini Street Board of Directors had previously authorized a common stock repurchase plan of up to $50.0 million, of which $40.4 million still remains available.

Repaid the remaining $10.0 million outstanding on the revolving line of credit component of the Company’s credit facility, leaving a term loan balance of $71.3 million.

“With a strong ca ... Read more »

ZUG, Switzerland - Thursday, 11. September 2025 AETOSWire Print 

Galderma will present a wealth of data including new findings showing the impact of modern living on sensitive skin and insights from the largest global survey conducted on the condition
Late-breaking data on Nemluvio’s® (nemolizumab) mode of action in atopic dermatitis (AD) and long-term safety and efficacy data in prurigo nodularis (PN) and moderate-to-severe AD up to two years will also be presented, supporting its potential as a frontline treatment that addresses key disease symptoms1-5
The company will also host a symposium on itch, industry hubs on sensitive skin and acne, and multiple Meet the Expert sessions, demonstrating its ongoing commitment to healthcare professional education and clinical excellence
 

(BUSINESS WIRE)--Galderma (SIX: GALD), the dermatology category leader, today announced it will unveil updates ... Read more »

Unique sports content orchestration platform builds momentum among SES’s customers as they redefine how they deliver sporting content around the world

Unique sports content orchestration platform builds momentum among SES’s customers as they redefine how they deliver sporting content around the world

Leading Balkan DTH provider adds capacity to consolidate its m:Sat TV platform at 23.5 degrees East and serve more customers across the region

Leading Balkan DTH provider adds capacity to consolidate its m:Sat TV platform at 23.5 degrees East and serve more customers across the region

Registered nurses worldwide can apply in their preferred language by 10^th November, 2025.

Dubai, United Arab Emirates, 10 September 2025:

SAINT PREX, Switzerland - Thursday, 11. September 2025

Nadofaragene firadenovec is the first and only non-replicating gene therapy administered intravesically, and it is already approved and launched in the US
This represents the first filing of a novel non-chemotherapy approach in non-muscle invasive bladder cancer (NMIBC) treatment
In the Japanese Phase 3 clinical trial, 75% complete response rate was achieved with single quarterly dosing, without requiring re-induction protocols1
This acceptance highlights Ferring's ongoing commitment to establish the new standard of care for BCG-unresponsive NMIBC
 

(BUSINESS WIRE)--Ferring Pharmaceuticals Co., Ltd. announced that the PMDA has accepted the NDA for nadofaragene firadenovec for review, following submission on August 27th, 2025. This non-replicating gene therapy, administered intravesically, offers patients with NMIBC a bladder-sparing treatment option. Nadofaragene firadenovec's ... Read more »